Vaxxinity (VAXX) Competitors $0.01 0.00 (-6.67%) As of 05/1/2025 09:45 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. NAVB, CALA, SCPS, EVLO, CMRA, GNCAQ, GNCA, ARDS, STAB, and SMFLShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Navidea Biopharmaceuticals (NAVB), Calithera Biosciences (CALA), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), and Smart for Life (SMFL). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Navidea Biopharmaceuticals Calithera Biosciences Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Statera Biopharma Smart for Life Navidea Biopharmaceuticals (NYSE:NAVB) and Vaxxinity (NASDAQ:VAXX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, community ranking, profitability, institutional ownership, valuation, risk, dividends and media sentiment. Which has preferable valuation and earnings, NAVB or VAXX? Navidea Biopharmaceuticals has higher revenue and earnings than Vaxxinity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K8.62-$15.18MN/AN/AVaxxinityN/AN/A-$56.93M-$0.45-0.03 Which has more volatility and risk, NAVB or VAXX? Navidea Biopharmaceuticals has a beta of 2.04, meaning that its share price is 104% more volatile than the S&P 500. Comparatively, Vaxxinity has a beta of -19.23, meaning that its share price is 2,023% less volatile than the S&P 500. Does the media refer more to NAVB or VAXX? In the previous week, Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Vaxxinity'saverage media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Vaxxinity Neutral Do insiders & institutionals hold more shares of NAVB or VAXX? 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. Comparatively, 82.9% of Vaxxinity shares are owned by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are owned by insiders. Comparatively, 64.1% of Vaxxinity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the MarketBeat Community believe in NAVB or VAXX? Vaxxinity received 5 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 38.46% of users gave Vaxxinity an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformNavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes84100.00% VaxxinityOutperform Votes538.46% Underperform Votes861.54% Is NAVB or VAXX more profitable? Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Vaxxinity N/A N/A N/A SummaryVaxxinity beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.77M$6.69B$5.47B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-0.037.3222.5118.54Price / SalesN/A241.49397.62103.35Price / CashN/A65.8538.1834.62Price / Book0.136.486.734.25Net Income-$56.93M$143.41M$3.22B$248.18M7 Day PerformanceN/A2.30%1.58%1.25%1 Month PerformanceN/A7.14%4.05%3.76%1 Year PerformanceN/A-2.61%15.75%5.28% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.01-6.7%N/A-87.8%$1.77MN/A-0.0390NAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-98.1%$60,000.00$8,126.000.0010Analyst ForecastCALACalithera BiosciencesN/A$0.01flatN/AN/A$24,000.00N/A0.0060SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009EVLOEvelo BiosciencesN/A$0.00flatN/A-98.9%$9,000.00N/A0.00120Options VolumeNews CoverageCMRAComera Life SciencesN/A$0.00flatN/A-99.7%$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070ARDSAridis PharmaceuticalsN/A$0.00flatN/A-99.8%$5,000.00$3.09M0.0030STABStatera BiopharmaN/A$0.00flatN/A-85.7%$5,000.00N/A0.0020SMFLSmart for LifeN/A$0.00+33.3%N/A-100.0%$3,000.00$11.11M0.00110Gap Up Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors Calithera Biosciences Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Statera Biopharma Competitors Smart for Life Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThe next market Nvidia is positioned to dominate …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
